Rallybio Corporation (RLYB)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks
Rallybio halts development of RLYB212 in a phase II study for the prevention of fetal and neonatal alloimmune thrombocytopenia. Stock falls.
Rallybio Corporation Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Andreas Halvorsen Viking Global Investors LP | 524,347.12 | $73.74M | $8.43M | -$65.32M | -88.57% |
Rallybio Corporation (RLYB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Rallybio Corporation ever had a stock split?
Rallybio Corporation Profile
| Biotechnology Industry | Healthcare Sector | Stephen Uden CEO | NASDAQ (NGS) Exchange | 75120L209 CUSIP |
| US Country | 15 Employees | - Last Dividend | 6 Feb 2026 Last Split | 29 Jul 2021 IPO Date |
Overview
Rallybio Corporation is a clinical-stage biotechnology company focused on the development and commercialization of innovative therapies for patients with severe and rare diseases. Founded in 2018 and based in New Haven, Connecticut, Rallybio leverages cutting-edge science and strategic collaborations with industry leaders such as AbCellera, Exscientia, and Johnson & Johnson. Through these partnerships, Rallybio aims to expedite the discovery, development, and commercialization of novel antibody-based and small molecule therapeutics targeted at rare disease populations. The company's dedication to addressing unmet medical needs in the rare disease space underlines its mission to transform the lives of patients dealing with life-altering conditions.
Products and Services
- RLYB212: A monoclonal anti-HPA-1a antibody, this leading product candidate has completed a Phase I clinical trial focused on the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). RLYB212's development signifies a critical step in addressing this rare but serious condition affecting pregnancies.
- RLYB211: Also aimed at the prevention of FNAIT, RLYB211 is another pivotal product in Rallybio's portfolio designed to safeguard fetal and neonatal health during pregnancy.
- RLYB114: A pegylated complement factor 5 (C5)-targeted Affibody molecule currently in preclinical development. RLYB114 is being investigated for its potential in treating complement-mediated ophthalmic diseases, representing Rallybio's entry into the ophthalmology sector.
- RLYB116: An inhibitor of complement component 5 (C5) that has completed a Phase 1 trial. RLYB116 holds promise for treating a range of diseases caused by complement dysregulation, showcasing Rallybio’s efforts in addressing complex immunological disorders.
- RLYB331: Still in preclinical development, this antibody targets severe anemia associated with ineffective erythropoiesis and iron overload. RLYB331 exemplifies Rallybio’s commitment to tackling rare hematological conditions.
In addition, Rallybio’s strategic alliances play a crucial role in bolstering its product pipeline. A notable partnership with AbCellera seeks to drive the discovery and commercialization of novel antibody-based therapeutics for rare diseases. Collaborations with Exscientia and Johnson & Johnson further underscore Rallybio’s comprehensive approach to developing therapeutic solutions for underserved patient populations, particularly in the realm of rare diseases.
